|Bid||36.23 x 2100|
|Ask||36.24 x 2200|
|Day's Range||36.13 - 36.29|
|52 Week Range||29.83 - 36.60|
|PE Ratio (TTM)||26.49|
|Dividend & Yield||1.28 (3.52%)|
|1y Target Est||N/A|
In the physics of business, the entropic forces that break down a system can also liberate energy. Hidden value is meant to be released from spin-offs and the like, especially when profit growth slows. ...
The London-listed consumer group is doing what activist Nelson Peltz wants Procter & Gamble to do—but M&A may be an ulterior motive.
Britain's Reckitt Benckiser will split its business into two divisions -- consumer healthcare and home and hygiene products -- to try to revive sales that are set to stall this year. The change follows ...
Reckitt Benckiser (RB.L) plans to reorganise its business into two distinct units, one for health and the other for hygiene and home products, as it tries to improve its flagging performance. The maker of Durex condoms, Nurofen tablets and Dettol cleaners announced the restructuring on Wednesday, along with its third-quarter sales figures. The British company made the decision to restructure after its June acquisition of U.S. baby formula maker Mead Johnson, which will account for roughly half of the larger health unit's sales.
Reckitt Benckiser Group Plc separated its home-care and health businesses, sharpening its focus on brands such as Durex condoms and Enfamil baby formula after a second cut in the sales forecast this year....
Results of a 32-patient study of a drug made by Ignyta Pharmaceuticals, a San Diego-based drugmaker, are a best case scenario for the company. The drug shrank tumors in 79% of patients and kept workingabout 10 months longer than the current drug, Pfizer’s Xalkori, did in earlier clinical trials.
Shares of Aerie Pharmaceuticals, Inc. (AERI) have moved up 15.8% in the last week on positive news for its lead drug, Rhopressa.
The quest for the “holy grail” of cardiovascular therapy - a drug that dramatically lowered LDL-c and raised HDL-c and which would hopefully reverse atherosclerosis - has ended ignominiously.
The pharmaceutical industry puts the cost of bringing a medicine from invention to pharmacy shelves at $2.7 billion. A new paper says it is 'just' $648 million. Unfortunately for pharmaceutical investors and people fighting to control drug prices, alike, the new number doesn’t stand up scrutiny.
Customers may be starting to shop for over-the-counter drugs in the same way they shop for groceries—with a keener eye for cost and content—and this could be painful for consumer-health companies.
A deal would give the company capital to do more deals but the decision also keeps the company's recently scratched plans to split into two separate companies alive. The division itself had about $3.4 ...
So far in October, of the 22 analysts covering Eli Lilly (LLY), four have suggested a “strong buy,” while ten analysts have suggested a “buy.”
Pharmaceutical third-quarter earnings are nearly upon us, and Guggenheim's Tony Butler and Allen Cha provide their thoughts on the upcoming results. Butler and Cha write that the hurricanes are a factor ...
T here’s been speculation about whether or not Pfizer (PFE) is planning to make a large acquisition, and Guggenheim’s Tony Butler takes on the question, writing that a smart deal could expand the pharma giant’s multiple. Butler notes that Pfizer’s management has stated that it’s aware of the need to create shareholder value, and he believes that the outcome hinges on a number of factors, including any potential tax reform/cash repatriation holiday, as well as clinical trial results. At the moment, Pfizer has a joint venture with Merck (MRK) to develop Bavencio, a PD-L1 antibody, but Butler wonders if it might be willing to step back if the data isn’t supportive, and if it might be willing to acquire a company with a different, PD-1 antibody—again if the data bears it out.
Pfizer (PFE) is looking at strategic options for its Consumer Healthcare business while Merck announced that it won't be seeking approval for its CETP inhibitor.